Blueprint Historical Income Statement

BPMC Stock

USD 93.87 0.28 0.30%

Historical analysis of Blueprint Medicines income statement accounts such as Interest Expense of 54.2 M, Selling General Administrative of 292.2 M or Gross Profit of 248.4 M can show how well Blueprint Medicines Corp performed in making a profits. Evaluating Blueprint Medicines income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Blueprint Medicines's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Blueprint Medicines Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Blueprint Medicines Corp is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

About Blueprint Income Statement Analysis

Blueprint Medicines Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Blueprint Medicines shareholders. The income statement also shows Blueprint investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Blueprint Medicines Income Statement Chart

At present, Blueprint Medicines' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 248.4 M, whereas Depreciation And Amortization is forecasted to decline to about 7.7 M.

Interest Expense Selling General Administrative Other Operating Expenses Research Development Ebitda

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Blueprint Medicines Corp. It is also known as Blueprint Medicines overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Blueprint Medicines' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Blueprint Medicines Corp current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

	2021	2022	2023	2024 (projected)
Interest Expense	7.4M	16.8M	51.6M	54.2M
Depreciation And Amortization	12.8M	20.1M	11.7M	7.7M

Interest Expense Depreciation And Amortization

Blueprint Medicines income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Total Revenue	Net Income From Continuing Ops	Interest Income	Non Operating Income Net Other	Net Interest Income	Reconciled Depreciation	Selling And Marketing Expenses	Tax Provision
Depreciation And Amortization		0.53	0.81	0.62	0.94	-0.6	-0.6	0.92	-0.58	0.0	0.94	-0.59	-0.3	-0.59	0.0	0.62	-0.59	0.87	0.04	-0.32	0.7	0.85	0.77
Interest Expense	0.53		0.9	0.47	0.59	-0.53	-0.54	0.52	-0.53	-0.17	0.59	-0.55	-0.69	-0.55	-0.06	0.37	-0.58	0.79	0.04	-0.75	0.96	0.75	0.47
Selling General Administrative	0.81	0.9		0.6	0.86	-0.67	-0.68	0.82	-0.67	-0.18	0.86	-0.68	-0.63	-0.69	0.07	0.54	-0.69	0.93	0.06	-0.67	0.97	0.93	0.72
Gross Profit	0.62	0.47	0.6		0.54	0.09	0.09	0.5	0.11	-0.37	0.54	0.09	-0.21	0.09	-0.06	0.95	0.09	0.72	-0.32	-0.12	0.5	0.57	0.27
Other Operating Expenses	0.94	0.59	0.86	0.54		-0.72	-0.72	0.99	-0.71	0.0	1.0	-0.72	-0.32	-0.72	0.07	0.55	-0.71	0.87	0.1	-0.36	0.73	0.88	0.7
Operating Income	-0.6	-0.53	-0.67	0.09	-0.72		1.0	-0.73	1.0	-0.16	-0.72	1.0	0.41	1.0	-0.01	0.14	1.0	-0.59	-0.18	0.49	-0.64	-0.67	-0.72
Ebit	-0.6	-0.54	-0.68	0.09	-0.72	1.0		-0.73	1.0	-0.16	-0.72	1.0	0.41	1.0	0.0	0.14	1.0	-0.59	-0.18	0.49	-0.64	-0.67	-0.72
Research Development	0.92	0.52	0.82	0.5	0.99	-0.73	-0.73		-0.72	0.09	0.99	-0.72	-0.22	-0.72	0.05	0.53	-0.71	0.85	0.13	-0.26	0.68	0.82	0.68
Ebitda	-0.58	-0.53	-0.67	0.11	-0.71	1.0	1.0	-0.72		-0.16	-0.71	1.0	0.4	1.0	0.0	0.16	1.0	-0.58	-0.18	0.49	-0.63	-0.65	-0.71
Cost Of Revenue	0.0	-0.17	-0.18	-0.37	0.0	-0.16	-0.16	0.09	-0.16		0.01	-0.13	0.67	-0.12	-0.44	-0.24	-0.17	-0.06	0.51	0.47	-0.18	-0.38	-0.28
Total Operating Expenses	0.94	0.59	0.86	0.54	1.0	-0.72	-0.72	0.99	-0.71	0.01		-0.71	-0.32	-0.71	0.06	0.56	-0.7	0.87	0.1	-0.35	0.73	0.87	0.7
Income Before Tax	-0.59	-0.55	-0.68	0.09	-0.72	1.0	1.0	-0.72	1.0	-0.13	-0.71		0.44	1.0	-0.03	0.14	1.0	-0.59	-0.18	0.52	-0.65	-0.68	-0.73
Total Other Income Expense Net	-0.3	-0.69	-0.63	-0.21	-0.32	0.41	0.41	-0.22	0.4	0.67	-0.32	0.44		0.45	-0.4	-0.1	0.42	-0.38	0.09	0.96	-0.71	-0.72	-0.62
Net Income	-0.59	-0.55	-0.69	0.09	-0.72	1.0	1.0	-0.72	1.0	-0.12	-0.71	1.0	0.45		-0.04	0.14	1.0	-0.59	-0.18	0.53	-0.66	-0.69	-0.73
Income Tax Expense	0.0	-0.06	0.07	-0.06	0.07	-0.01	0.0	0.05	0.0	-0.44	0.06	-0.03	-0.4	-0.04		0.08	0.01	-0.22	0.49	-0.43	0.09	0.25	0.27
Total Revenue	0.62	0.37	0.54	0.95	0.55	0.14	0.14	0.53	0.16	-0.24	0.56	0.14	-0.1	0.14	0.08		0.14	0.63	-0.08	-0.05	0.43	0.51	0.2
Net Income From Continuing Ops	-0.59	-0.58	-0.69	0.09	-0.71	1.0	1.0	-0.71	1.0	-0.17	-0.7	1.0	0.42	1.0	0.01	0.14		-0.6	-0.2	0.52	-0.67	-0.66	-0.7
Interest Income	0.87	0.79	0.93	0.72	0.87	-0.59	-0.59	0.85	-0.58	-0.06	0.87	-0.59	-0.38	-0.59	-0.22	0.63	-0.6		-0.14	-0.38	0.85	0.84	0.63
Non Operating Income Net Other	0.04	0.04	0.06	-0.32	0.1	-0.18	-0.18	0.13	-0.18	0.51	0.1	-0.18	0.09	-0.18	0.49	-0.08	-0.2	-0.14		-0.17	0.13	-0.02	0.02
Net Interest Income	-0.32	-0.75	-0.67	-0.12	-0.36	0.49	0.49	-0.26	0.49	0.47	-0.35	0.52	0.96	0.53	-0.43	-0.05	0.52	-0.38	-0.17		-0.78	-0.71	-0.61
Reconciled Depreciation	0.7	0.96	0.97	0.5	0.73	-0.64	-0.64	0.68	-0.63	-0.18	0.73	-0.65	-0.71	-0.66	0.09	0.43	-0.67	0.85	0.13	-0.78		0.87	0.66
Selling And Marketing Expenses	0.85	0.75	0.93	0.57	0.88	-0.67	-0.67	0.82	-0.65	-0.38	0.87	-0.68	-0.72	-0.69	0.25	0.51	-0.66	0.84	-0.02	-0.71	0.87		0.84
Tax Provision	0.77	0.47	0.72	0.27	0.7	-0.72	-0.72	0.68	-0.71	-0.28	0.7	-0.73	-0.62	-0.73	0.27	0.2	-0.7	0.63	0.02	-0.61	0.66	0.84

Click cells to compare fundamentals

Blueprint Medicines Account Relationship Matchups

Blueprint Medicines income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	10.3M	12.4M	12.8M	20.1M	11.7M	7.7M
Interest Expense	13.7M	12.8M	7.4M	16.8M	51.6M	54.2M
Selling General Administrative	96.4M	148.3M	181.8M	219.3M	278.2M	292.2M
Gross Profit	66.5M	793.3M	162.1M	186.2M	236.6M	248.4M
Other Operating Expenses	427.8M	485.0M	822.1M	741.6M	735.7M	390.0M
Operating Income	(366.6M)	302.1M	(648.5M)	(549.3M)	(486.3M)	(462.0M)
Ebit	(371.6M)	296.4M	(641.1M)	(535.5M)	(486.3M)	(462.0M)
Research Development	331.5M	326.9M	601.0M	477.4M	427.7M	273.0M
Ebitda	(361.3M)	308.7M	(628.3M)	(515.4M)	(474.6M)	(450.9M)
Cost Of Revenue	331.5M	425K	17.9M	17.8M	12.8M	12.2M
Total Operating Expenses	427.8M	484.6M	804.1M	723.7M	722.9M	385.2M
Income Before Tax	(347.7M)	314.9M	(641.1M)	(552.3M)	(506.0M)	(480.7M)
Total Other Income Expense Net	18.9M	6.2M	897K	(14.8M)	(19.7M)	(18.8M)
Net Income	(328.7M)	313.9M	(644.1M)	(557.5M)	(507.0M)	(481.6M)
Income Tax Expense	(19.0M)	1.1M	3.0M	5.2M	968K	1.0M
Total Revenue	66.5M	793.7M	180.1M	204.0M	249.4M	175.9M
Net Income From Continuing Ops	(414.2M)	313.9M	(644.1M)	(557.5M)	(554.7M)	(527.0M)
Net Income Applicable To Common Shares	(347.7M)	313.9M	(644.1M)	(557.5M)	(501.8M)	(476.7M)
Non Operating Income Net Other	(100K)	(366K)	(1.5M)	2.0M	1.8M	1.4M
Net Interest Income	13.7M	6.6M	2.4M	(16.8M)	(22.9M)	(21.7M)
Reconciled Depreciation	5.3M	6.6M	6.5M	11.7M	17.2M	18.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:

How To Invest In Blueprint

Details

Is Blueprint Stock a good investment?

Details

What is Blueprint Medicines' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.09)

Revenue Per Share

6.986

Quarterly Revenue Growth

1.266

Return On Assets

(0.15)

Return On Equity

(0.50)

The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Blueprint Historical Income Statement

About Blueprint Income Statement Analysis

Blueprint Medicines Income Statement Chart

Interest Expense

Other Operating Expenses

Blueprint Medicines income statement Correlations

Blueprint Medicines Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Blueprint Medicines income statement Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Net Income From Continuing Ops	+ 1.0	Operating Income

Reconciled Depreciation	- 0.78	Net Interest Income
Net Interest Income	- 0.75	Interest Expense
Tax Provision	- 0.73	Net Income
Tax Provision	- 0.73	Income Before Tax
Research Development	- 0.73	Ebit
Research Development	- 0.73	Operating Income